Star Update Podcast - Cardiology News Summaries

1-Month Versus 12-Month Dual Antiplatelet Therapy for Patients with Chronic Total Occlusion After Successful Percutaneous Coronary Intervention Drugs Aging. 2025 Aug 2. doi: 10.1007/s40266-025-01235z.  Abstract Purpose: Compared with long-term dual antiplatelet therapy (DAPT, aspirin with clopidogrel or ticagrelor), short-term DAPT followed by single antiplatelet therapy (SAPT, clopidogrel or tica...

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction:Design paper ESC Heart Fail. 2025 Aug;12(4):3134-3144. doi: 10.1002/ehf2.15294  Abstract Background:  Sodium glucose co-transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists(MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or prese...

ST-elevation myocardial infarction and air pollution: relationship between hourly air pollution and cardiovascular risk factors J Cardiovasc Med (Hagerstown). 2025 Aug 1;26(8):412-419.  Abstract Objective: Air pollution contributes to cardiovascular diseases through oxidative stress, inflammation, autonomicnervous system imbalance, and direct particle translocation. This study examines the relatio...

A Retrospective Cohort Study on Long-TermOutcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion Am J Cardiovasc Drugs. 2025 Jul 12. doi:10.1007/s40256-025-00750-z. Abstract Background:  Chronic total occlusion (CTO) affects 15-25% of patients undergoing coronary angiography, and successful percutaneous coronary intervention (PCI) c...

Early β-Blocker Use and Clinical Outcomesin Acute Myocardial Injury: A Retrospective Cohort Study Am J Med. 2025 Jul;138(7):1090-1098.e6. Abstract Background:  Acute myocardial injury is defined by elevated cardiac troponin levels with a rising and/or falling pattern, and is associated with increased mortality risk compared topatients without myocardial injury. The role of β-blockers in patients w...

Combined effects of clonal hematopoiesis of intermediate potential and P2Y12 inhibitors on outcomes of patients with ST-segment elevation myocardial infarction: A prospective study https://doi.org/10.1016/j.phrs.2025.107852   Abstract Clonal hematopoiesis of intermediate potential (CHIP) is a prominent risk factor for atherosclerosis, but effectivemedications for Clonal hematopoiesis of intermedia...

Effects of moderate physical trainingprogram in post-myocardial infarction patients with arterial hypertension Eur J Transl Myol. 2025 Jul 10. doi: 10.4081/ejtm.2025.13943   Abstract The clinical effectiveness of physical training in a cardiac rehabilitation program (CRP) was assessed in hypertensive(AH), post-myocardial infarction (MI) patients. 206 patients were randomized into a physically trai...

The 2025 Guideline for the Management of Patients With Acute Coronary Syndromes: Asian Perspective https://www.jacc.org/doi/full/10.1016/j.jacc.2025.04.011 The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for theManagement of Patients with Acute Coronary Syndromes introduces key updates that may influence global clinical practice. Given Asia’s immense population and regional diversity, assessing how th...

Exploring the Impact of Beta-Blockers Post-Acute Myocardial Infarction in Patients with Preserved Ejection Fraction: A Meta-Analysis J. Clin. Med.  2025,  14 (11), 3969;  https://doi.org/10.3390/jcm14113969  Abstract Background/Objectives: Previous research has establishedthat beta-blockers significantly reduce all-cause mortality, cardiovascular mortality, and recurrent acute myocardial infarctio...

Pragmatic Use of Ticagrelor: ImprovingOutcomes in Medical Management of Acute Coronary Syndrome (PracTiCal India Study) Journal of Indian College of Cardiology  ():10.4103/jicc.jicc_73_24, June 05, 2025. |  DOI:  10.4103/jicc.jicc_73_24 Abstract Background:  The utilization of ticagrelor in the medical management ofacute coronary syndrome (ACS) has been extensively explored in interventions such a...

Antiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: KeyRecommendations JACC . 2025 Jun, 85 (22) 2074–2078   The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for theManagement of Patients With Acute Coronary Syndromes (ACS), published in this issue of JACC, replaces the prior U.S. guidelines on the management of ST-segment and non–ST-segment elevation ACS....

Effect of Body Mass Index in Patients With Cardiogenic Shock Requiring Microaxial Flow Pump JACC: Asia . May 04, 2025. Epublished DOI:10.1016/j.jacasi.2025.03.003 Abstract Background The impact of obesity on mortality in patients with cardiogenic shock (CS) requiring microaxial flow pumps (mAFP) remains undetermined.   Objectives This study investigated the effect of body mass index (BMI) on morta...

The Impact of Preoperative P2Y12 Inhibitors on Short- and Long-Term Outcomes Following Percutaneous CoronaryIntervention DOI:  10.1016/j.jscai.2025.103226 ExternalLink   Background The preoperative usage of P2Y12 inhibitors primarily aim to reduce thrombotic complications for percutaneous coronary intervention (PCI), however, there is limited data on how these medications impact rates of adverse o...

Incidence and Risk Factors of De Novo Postpartum Hypertension: Understanding Links to Long-Term Cardiovascular Risk JACC Adv . 2025 Jun, 4 (6_Part_1) 101756   Abstract Background Individuals developing hypertensive disorders of pregnancy face a 2- to 5-fold risk of long-term cardiovascular disease. Limited data exist on de novo postpartum hypertension (dnPPHTN), where those normotensive during pre...

Aspirin vs Clopidogrel vs Ticagrelor Monotherapy Compared to 12 Months of DAPT Following PCI; A Systematic Review and Meta-Analysis DOI:  10.1016/j.jscai.2025.103158 ExternalLink   Background Short-term Dual Antiplatelet Therapy (DAPT) may reduce the risk of bleeding after Percutaneous Coronary Intervention (PCI) as compared to the standard 12 months of Dual Antiplatelet Therapy . However, it may...

Does Timing of Coronary Artery Bypass Grafting after ST-Elevation Myocardial Infarction Impact Early- and Long-Term Outcomes? DOI: 10.1055/s-0044-1787851  Abstract Background:  The optimal timing of surgicalrevascularization after ST-elevation myocardial infarction (STEMI) is controversial, with some suggesting higher mortality rates in patients undergoing early surgery. The aim of the study is to...

Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a DayClopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention DOI: 10.1016/j.ahj.2025.03.021  Abstract Background: Ticagrelor has been proven superior toclopidogrel in reducing adverse cardiovascular events in pa...

In-hospital use of beta-blockers for critically ill patients with acute heart failure: Whether and when to initiate DOI: 10.1016/j.jclinane.2025.111824  Abstract Background:  The use of beta-blockers during hospitalization for acute heart failure (AHF) remains controversial. This study aimed to investigate whether beta-blocker use isassociated with a reduced risk of mortality in critically ill pat...

1.  Dual antiplatelet therapy is recommended for patients with acute coronary syndromes (ACS). Ticagrelor or prasugrel is recommended in preference to clopidogrel in patients with ACS who are undergoing percutaneous coronary intervention (PCI). In patients with non–ST-segment elevation ACS who are scheduled for an invasive strategy with timing of angiography to be >24 hours, upstream treatment...

The “Silent Enemy” Called Renal Artery Stenosis: A Mini-Review: J. Vasc. Dis. 2025, 4(1), 10; https://doi.org/10.3390/jvd4010010 Renal artery stenosis (RAS) is a vascular condition characterized by narrowing of one or both renal arteries, leading to reduced blood flow to the kidneys, activation of the renin–angiotensin–aldosterone system (RAAS), and subsequent renovascular hypertension. Overactiva...

Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure withreduced ejection fraction https://link.springer.com/article/10.1186/s43044-025-00629-z Heart failure (HF) is a significant global health issue. Appropriate and timely treatment at target doses significantly reduces mortality and enhances quality of life. However, studies indicate subopti...

Impact of Metabolic Syndrome on Clinical Profile and Prognosis in Patients with Acute ST-Elevation MyocardialInfarction: a Cross-Sectional Study https://link.springer.com/article/10.1007/s42399-025-01822-6 Abstract Metabolic syndrome (MS) has gained attention as a newly discovered risk factor for coronary artery disease (CAD).Studies have demonstrated that individuals with MS have a higher risk fo...

Early β-Blocker Use and Clinical Outcomes in Acute Myocardial Injury: A Retrospective Cohort Study https://doi.org/10.1016/j.amjmed.2025.02.029 Abstract Background Acute myocardial injury is defined by elevated cardiactroponin (cTn) levels with a rising and/or falling pattern, and is associated with increased mortality risk compared to patients without myocardial injury. The role of β-blockers in...

Impact of controlled stepwise reperfusion during primary percutaneous coronary intervention on patients with ST-elevation myocardial infarction  Abstract Objective: The aim of this study is to examine the impact of controlled stepwise reperfusion by modulating pre-dilation balloonpressure during primary percutaneous coronary interventions (PPCI) in patients with ST-elevation myocardial infarction...

De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systemic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials Ann Intern Med . 2025 Feb 18. doi: 10.7326/ANNALS-24-03102. Abstract Background:  The role of transitioning from shortdual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute cor...